路径独立的正调节器C1允许识别活性Y4受体的相关位置
Corinna Schüß1, Oanh Vu2, Tim Pelczyk3
1Institute of Biochemistry, Leipzig University, 04103, Leipzig, Germany. corinna.schuess@uni-leipzig.de.
Cellular and molecular life sciences : CMLS
|January 13, 2026
概括
研究人员确定了C1,一种新的阳性全调节器 (PAM) 对神经Y4受体 (Y4R). C1增强了Y4R信号传递和带结合,为和能量平衡调节提供了新的治疗途径.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 生物化学 生物化学
背景情况:
- 神经Y4受体 (Y4R) 和其连接体胰腺多 (PP) 是和能量平衡的关键调节者.
- Y4R代表了代谢和食障碍的重要药理目标.
研究的目的:
- 描述Y4R的一种新型正调节器 (PAM),被指定为C1.1.
- 阐明C1在Y4R的活动背后的结构和功能机制.
主要方法:
- 生物化学测试以评估G蛋白信号传递,配体结合和阿雷斯-3的招募.
- 使用C1.1的类型的结构-活动关系研究.
- 位点定向的突变发生和嵌合体构造 (Y4R/Y1R) 来识别关键的受体域.
- 计算对接以精确确定关键氨基酸残留物.
主要成果:
- 鉴定出C1是一种强大的Y4R PAM,增强G蛋白信号传递,带结合和阿雷斯-3招募.
- 在C1中的乙酸乙烯部分对Y4R亲和力和G蛋白通路活性至关重要.
- C1对Y4R具有很高的选择性,而不会影响Y1R,Y2R或Y5R信号.
- C1增强了低亲和度激动剂 (NPY,PYY) 的信号传递,并增强了内源性联结亲和度.
- 关键的Y4R域和涉及C1的全调节的特定残留物通过嵌合体和突变遗传学研究被确定.
结论:
- C1代表了一种新的和选择性的药理学工具,用于调节Y4R活性.
- 这些发现为GPCRs,特别是Y4R.的全调节机制提供了洞察力.
- C1及其作用机制为针对和能量平衡的治疗策略提供了潜力.
相关概念视频
Allosteric Proteins-ATCase
6.5K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
6.5K
Ligand Binding and Linkage
5.5K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.5K
The Two-State Receptor Model
3.0K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
3.0K
Allosteric Regulation
62.9K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
62.9K
Ligand-Gated Ion Channel Receptor: Gating Mechanism
3.8K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
3.8K
Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K


